Last reviewed · How we verify
CLS006
CLS006 is a topical agent developed for dermatological conditions, likely targeting inflammatory or proliferative skin pathways.
CLS006 is a topical agent developed for dermatological conditions, likely targeting inflammatory or proliferative skin pathways. Used for Investigational dermatological indication (specific indication not publicly disclosed).
At a glance
| Generic name | CLS006 |
|---|---|
| Sponsor | Maruho Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
CLS006 is an investigational dermatological compound in Phase 3 development by Maruho Co., Ltd., a Japanese pharmaceutical company specializing in dermatology. The specific molecular mechanism remains proprietary and not widely disclosed in public literature. Given Maruho's therapeutic focus, it is likely designed to address inflammatory skin diseases or other dermatological conditions through a topical formulation.
Approved indications
- Investigational dermatological indication (specific indication not publicly disclosed)
Common side effects
Key clinical trials
- A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts (PHASE3)
- A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CLS006 CI brief — competitive landscape report
- CLS006 updates RSS · CI watch RSS
- Maruho Co., Ltd. portfolio CI